ALTME TME PHARMA N.V.

TME Pharma Announces Oral Presentation of NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma at ESMO Congress 2024

BERLIN--(BUSINESS WIRE)--

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that an abstract featuring results from the NOX-A12 GLORIA Phase 1/2 trial in first-line brain cancer (glioblastoma) has been selected for presentation at the European Society for Medical Oncology (ESMO) Congress taking place in Barcelona, Spain, September 13-17, 2024.

The oral presentation will provide further analysis of the dual inhibition of NOX-A12 and bevacizumab in glioblastoma in the expansion arm of the GLORIA Phase 1/2 trial. The full abstract will be published online via the . 00:05 a.m. CEST on Monday, September 09, 2024. It will be available concurrently on the TME Pharma website.

Title: Dual inhibition of postradiogenic angio-vasculogenesis in glioblastoma: Results of the phase 1/2 GLORIA trial

Presenter: Dr. Frank A. Giordano, Chair of the Department of Radiation Oncology, University Medical Center Mannheim, Germany

Session: Mini oral session: CNS tumors

Time and Date: 08.30-8.35 a.m. CEST, Sunday, September 15, 2024

About TME Pharma

TME Pharma is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. The company’s oncology-focused pipeline is designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair.

EN
17/07/2024

Underlying

ALTMETME PHARMA N.V.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TME PHARMA N.V.

 PRESS RELEASE
Free
ALTME TME PHARMA N.V.

TME Pharma extends financial runway to over 12 months

TME Pharma extends financial runway to over 12 months TME Pharma extends financial runway to over 12 months Berlin, Germany, March 9, 2025, 08.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, is pleased to announce that certain lenders have accepted to extend the maturity of their loan by a further 12 months. TME Pharma now has cash runway into Q2 2027. An agreement has been reached with certain lenders who participated in the May and August 2025 fundraisings (i...

March 9, 2026 1 EN
 PRESS RELEASE
Free
ALTME TME PHARMA N.V.

TME PHARMA PROLONGE SA CAPACITÉ FINANCIÈRE À PLUS DE 12 MOIS

TME PHARMA PROLONGE SA CAPACITÉ FINANCIÈRE À PLUS DE 12 MOIS TME PHARMA PROLONGE SA CAPACITÉ FINANCIÈRE À PLUS DE 12 MOIS Berlin, Allemagne, 9 mars 2025, 8 h 00 CET – TME Pharma N.V. (Euronext Growth Paris : ALTME), une société de biotechnologie au stade clinique spécialisée dans le développement de nouvelles thérapies pour le cancer et les maladies oculaires, a le plaisir d'annoncer que certains prêteurs ont accepté de prolonger la durée de leur prêt de 12 mois supplémentaires. TME Pharma dispose désormais d'une trésorerie suffisante jusqu'au deuxième trimestre 2027. Un accord a été conc...

March 9, 2026 1 EN
 PRESS RELEASE
Free
ALTME TME PHARMA N.V.

TME Pharma provides update on its activities

TME Pharma provides update on its activities TME Pharma provides update on its activities Berlin, Germany, January 5, 2025, 08.00 CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, announced today updates on its research and development activities and its potential investment strategies. NOX-E36 developmentsTME Pharma announces the initiation of a subsequent study for NOX-E36 and the simultaneous termination of its collaboration with the Singapore Eye Research Institut...

January 5, 2026 1 EN
 PRESS RELEASE
Free
ALTME TME PHARMA N.V.

TME PHARMA FAIT LE POINT SUR SES ACTIVITÉS

TME PHARMA FAIT LE POINT SUR SES ACTIVITÉS TME PHARMA FAIT LE POINT SUR SES ACTIVITÉS Berlin, Allemagne, 5 janvier 2025, 8 h 00 CET – TME Pharma N.V. (Euronext Growth Paris : ALTME), une société de biotechnologie au stade clinique spécialisée dans le développement de thérapies innovantes pour le cancer et les maladies oculaires, a annoncé aujourd'hui des mises à jour concernant ses activités de recherche et développement et ses stratégies d'investissement potentielles. Développements concernant le NOX-E36TME Pharma annonce le lancement d'une étude complémentaire sur le NOX-E36 et simultan...

January 5, 2026 1 EN
 PRESS RELEASE
Free
ALTME TME PHARMA N.V.

TME Pharma announces receipt of agreements in principle to extend cert...

TME Pharma announces receipt of agreements in principle to extend certain bond agreements TME Pharma announces receipt of agreements in principle to extend certain bond agreements Berlin, Germany, November 17, 2025, 08.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, announced today that certain holders of the bonds issued in May and August, 2025 have agreed in principle to extend the maturity of the bonds for a one year period.  These bond holders, Diede van den...

November 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch